Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

NCT01545947 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer

Interventions

DRUG: CC-223, erlotinib
DRUG: CC-223, oral azacitidine
DRUG: CC-223, oral azacitidine

Sponsor

Celgene